Pharmaceuticals

Enveric Biosciences

Enveric Biosciences released FY2026 Q1 earnings on May 15 EST, actual revenue USD 0, actual EPS USD -1.0814

Enveric Reports Positive Preclinical Results for EB-003 in PTSD Model

Enveric Biosciences released FY2025 Q4 earnings on March 27 (EST), actual revenue USD 0, actual EPS USD -6.1245

Enveric Biosciences released FY2025 earnings on March 27 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -36.2437 (forecast USD -10.32)

Enveric Biosciences released FY2025 9 Months earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -37.0437

Enveric Biosciences released FY2025 Q3 earnings on November 14 (EST), actual revenue USD 0, actual EPS USD -10.8099

Enveric Completes Key CMC Milestones for EB-003, Paving the Way for Clinical Trials

Enveric Biosciences released FY2025 Q2 earnings on August 14 (EST), actual revenue USD 0, actual EPS USD -0.9705 (forecast EPS USD -5.25)

Enveric Biosciences released FY2025 Semi-Annual Earnings on August 14 (EST), Actual Revenue: USD 0, Actual EPS: USD -25.7634

Enveric Biosciences Inc. Announces Positive Preclinical Results for PTSD Drug EB-003

Enveric Announces New Data on EB-003 and Advances Development

Enveric Biosciences Receives Patent for Novel Neuroplastic Compound

Enveric Biosciences Obtains Patent for Sleep and CNS Disorders

Enveric Announces Positive Preclinical Results for Depression Drug Candidate EB-003

Enveric Submits Patent Application for Neurodegenerative Disease Treatment

Enveric Biosciences released FY2025 Q1 earnings on May 14 EST, actual revenue USD 0 (forecast USD --), actual EPS USD -14.5845 (forecast USD -71.9999)

Enveric Biosciences Obtains Patent for Addiction and Neuropsychiatric Disorders

Enveric Biosciences released FY2024 Q4 earnings on March 28 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -57.5896 (forecast USD -2.76)

Enveric Biosciences released FY2024 Annual Earnings on March 28 (EST), Actual Revenue: USD 0 (Forecast: USD 0), Actual EPS: USD -228.4763 (Forecast: USD -13.92)

Enveric Biosciences Inc expects a loss of 23 cents per share, with an analyst rating of Buy

OPTIMI HEALTH CORP

HCW Biologics

GCL Global

Silexion Therapeutics

Micware

BiomX

Vida Global

MetaVia

MicroAlgo

Tradr 2X Long XNDU Daily ETF

ENVB

LABU

Enveric Biosciences shares are trading lower. The company announced preclinical in vitro results showing no photoreactive potential for EB‑003, further derisking its neuropsychiatric program.

benzinga_article

SPDR S&P Biotech

Direxion S&P Biotech Bull 3X

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

VanEck Biotech ETF

Earnings Watch

Enveric Biosciences | 8-K: FY2026 Q1 EPS: USD -1.08

Enveric Biosciences Inc. (NASDAQ:ENVB) has highlighted promising preclinical data for its PTSD treatment candidate, EB-003, which shows rapid reductions in fear responses. This comes amid a policy shift supporting psychedelic therapies, backed by an executive order from President Trump. CEO Joseph Tucker emphasized EB-003's unique approach targeting neuroplasticity and mood pathways, potentially offering broader benefits for neuropsychiatric conditions. Despite a 62.4% rise in stock over the past month, shares remained unchanged at $3.41 during premarket trading.

S&P 500

Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health Therapies

EBAY

eBay pre-market up 8.58%; Enveric Biosciences pre-market up 8.52%; Credit Suisse High Yield Credit Fund pre-market up 244.83%; Skycorp Solar pre-market up 92.67%; Rallybio pre-market up 51.20%

Price Alert

eBay

Credit Suisse High Yield Credit Fund

Skycorp Solar

Rallybio

Pre-market hot trades in US stocks: eBay up 8.58% in pre-market; Enveric Biosciences up 8.52% in pre-market

SBIO

Enveric Biosciences (ENVB) filed a corrected proxy statement for its May 28, 2026, annual meeting, clarifying the reverse stock split range from 1-for-50 to 1-for-15. The meeting will also address the election of six directors, an advisory say-on-pay resolution, and a significant increase in authorized shares to 5 billion. Despite a neutral rating from Spark due to weak financial performance, the company aims to maintain listing flexibility and capital-raising capacity. ENVB's current market cap is $10.25M, with ongoing losses impacting valuation.

Tip Ranks

ALPS Medical Breakthrough

Enveric Biosciences Corrects Reverse Stock Split Proxy Disclosure

FATN

AKAN

HCAI

At 8:00 a.m. ET on Thursday, notable premarket trading activity is observed in stocks such as HCAI, FATN, ENVB, and AKAN, indicating potential trading opportunities. HCAI leads with a 95% increase, while ENVB sees a 31% decline. Premarket analysis is crucial for traders to identify momentum and potential price movements before the market opens.

rttnews

Fatpipe

Akanda

Huachen AI Parking Management Tech

Everspin Tech

Viavi Solutions

Bandwidth

Impinj

TTM Tech

Benchmark Electronics

Baiya

Rising Dragon Acquisition

Cheetah Net Supply Chain

Meta Platforms

Willis Towers Watson

Check Point Software

Sensient Tech

AXIL Brands

Wayfair

Climb Global Solutions

RISING DRAGON ACQUISITION CORP COM USD0.0001 15/11/2028 (SUBS/RT)

Morning Market Movers: HCAI, FATN, ENVB, AKAN See Big Swings

PRCT

OSRH

GKOS

OPCH

In Thursday's pre-market session, Akanda (NASDAQ:AKAN) saw a significant gain of 21.7%, reaching $31.64, while Glaukos (NYSE:GKOS) rose 15.42% to $135.0. Other gainers included PROCEPT BioRobotics (NASDAQ:PRCT) up 15.33% and OSR Holdings (NASDAQ:OSRH) up 15.23%. Conversely, Enveric Biosciences (NASDAQ:ENVB) experienced the largest decline, falling 31.2% to $3.55. Option Care Health (NASDAQ:OPCH) and Adlai Nortye (NASDAQ:ANL) also saw notable decreases of 14.37% and 13.63%, respectively.

Enveric Biosciences(ENVB.US)